Jeff Fairman - Dec 30, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
Jeff Fairman, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Dec 30, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 03:33 PM
Previous filing
Oct 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 17.8K Dec 30, 2022 Direct F1
holding PCVX Common Stock 286K Dec 30, 2022 By Fairman Family Trust
holding PCVX Common Stock 50K Dec 30, 2022 By AF 2020 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (Right to Buy) Award $0 +15K $0.00 15K Dec 30, 2022 Common Stock 15K $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jeff Fairman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.